CORE SECTOR SUBDUED, AS REFINING HIT HARD. Core sector growth for April 2025 at 0.49% marked the lowest level in 8 months. It ...

The board of directors has proposed a final dividend of ₹6 per equity share of the face value of ₹10 (60%) for FY25 ...

The company reported revenue from operations at ₹1,000 crore, up 2.7%YoY over ₹973.6 crore reported in Q4 FY24.

Most of the IPO proceeds will be used for deleveraging, allowing for better margins and financial flexibility.

Headline CPI drops. There’s more to the story as core CPI remains elevated. Will RBI continue its accommodative stance as ...

The scope of works comprises survey, design, supply, installation, testing and commissioning of KAVACH equipment and any ...

On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.

Max Healthcare Institute announced a 21% year-on-year growth in its March quarter net profit at ₹376 Crore. The company ...

If you look at the 8 hybrid fund categories (including solution-oriented funds) across 12 months, then you have 96 data flow ...

The issue may be done through public offers or private placements. This subject to market conditions, and regulatory ...

This latest order enlarges TCS’s continued engagement with BSNL to modernise the state-run telecom operator’s mobile infrastructure.

As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.